Larry Rubinstein

66.5k total citations · 7 hit papers
196 papers, 47.6k citations indexed

About

Larry Rubinstein is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Larry Rubinstein has authored 196 papers receiving a total of 47.6k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 67 papers in Molecular Biology and 46 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Larry Rubinstein's work include Statistical Methods in Clinical Trials (41 papers), Cancer Genomics and Diagnostics (33 papers) and Lung Cancer Treatments and Mutations (28 papers). Larry Rubinstein is often cited by papers focused on Statistical Methods in Clinical Trials (41 papers), Cancer Genomics and Diagnostics (33 papers) and Lung Cancer Treatments and Mutations (28 papers). Larry Rubinstein collaborates with scholars based in United States, Malaysia and Canada. Larry Rubinstein's co-authors include Susan G. Arbuck, Richard Kaplan, Michaele C. Christian, Daniel J. Sargent, Janet Dancey, Lori E. Dodd, Lawrence H. Schwartz, Margaret Mooney, Lalitha Shankar and Jan Bogaerts and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

Larry Rubinstein

185 papers receiving 46.7k citations

Hit Papers

New response evaluation criteria in... 1983 2026 1997 2011 2008 2000 1995 1990 1989 5.0k 10.0k 15.0k 20.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    2008 20.7k citations Larry Rubinstein et al. profile →
  2. New Guidelines to Evaluate the Response to Treatment in Solid Tumors
    2000 13.6k citations Larry Rubinstein et al. JNCI Journal of the National Cancer Institute profile →
  3. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer
    1995 2.1k citations Larry Rubinstein et al. profile →
  4. Comparison of In Vitro Anticancer-Drug-Screening Data Generated With a Tetrazolium Assay Versus a Protein Assay Against a Diverse Panel of Human Tumor Cell Lines
    1990 859 citations Larry Rubinstein, Richard Simon et al. JNCI Journal of the National Cancer Institute profile →
  5. Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm
    1989 816 citations Larry Rubinstein et al. JNCI Journal of the National Cancer Institute profile →
  6. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
    2001 621 citations Larry Rubinstein, Melinda G. Hollingshead et al. profile →
  7. Modern thirty-day operative mortality for surgical resections in lung cancer
    1983 511 citations Paul Thomas, Larry Rubinstein et al. Journal of Thoracic and Cardiovascular Surgery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Larry Rubinstein United States 54 22.4k 20.2k 9.1k 7.4k 7.3k 196 47.6k
Richard Kaplan United Kingdom 48 22.4k 1.0× 20.2k 1.0× 7.3k 0.8× 7.5k 1.0× 7.8k 1.1× 173 46.0k
Janet Dancey United States 68 19.9k 0.9× 15.4k 0.8× 8.6k 0.9× 5.4k 0.7× 5.5k 0.8× 205 38.3k
Susan G. Arbuck United States 41 21.8k 1.0× 16.5k 0.8× 7.9k 0.9× 6.4k 0.9× 6.9k 0.9× 88 40.5k
Denis Lacombe Belgium 34 15.2k 0.7× 14.2k 0.7× 9.2k 1.0× 7.1k 1.0× 4.7k 0.6× 113 41.0k
Jaap Verweij Netherlands 100 28.2k 1.3× 22.3k 1.1× 13.7k 1.5× 3.6k 0.5× 8.8k 1.2× 621 55.4k
Elizabeth A. Eisenhauer Canada 61 15.2k 0.7× 12.7k 0.6× 12.0k 1.3× 5.4k 0.7× 4.1k 0.6× 213 41.9k
Lawrence H. Schwartz United States 80 21.2k 0.9× 20.6k 1.0× 5.9k 0.6× 16.5k 2.2× 8.4k 1.1× 395 52.0k
Jan Bogaerts Belgium 39 16.2k 0.7× 12.0k 0.6× 4.5k 0.5× 5.2k 0.7× 5.3k 0.7× 114 30.1k
Kenneth R. Hess United States 98 15.4k 0.7× 14.8k 0.7× 9.9k 1.1× 3.7k 0.5× 6.4k 0.9× 509 41.8k
John D. Hainsworth United States 82 21.5k 1.0× 12.3k 0.6× 10.1k 1.1× 3.2k 0.4× 5.3k 0.7× 631 37.1k

Countries citing papers authored by Larry Rubinstein

Since Specialization
Citations

This map shows the geographic impact of Larry Rubinstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larry Rubinstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larry Rubinstein more than expected).

Fields of papers citing papers by Larry Rubinstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larry Rubinstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larry Rubinstein. The network helps show where Larry Rubinstein may publish in the future.

Co-authorship network of co-authors of Larry Rubinstein

This figure shows the co-authorship network connecting the top 25 collaborators of Larry Rubinstein. A scholar is included among the top collaborators of Larry Rubinstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Larry Rubinstein. Larry Rubinstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
McCourt, Carolyn K., Zihan Wei, Kevin Kalinsky, et al.. (2025). Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K. Clinical Cancer Research. 31(23). 4912–4919. 2 indexed citations
3.
O’Hara, Mark H., Opeyemi A. Jegede, Mark A. Dickson, et al.. (2024). Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C. Clinical Cancer Research. 31(1). 56–64. 1 indexed citations
4.
Salama, April K.S., Victoria Wang, Erin Macrae, et al.. (2024). Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H.. Journal of Clinical Oncology. 42(16_suppl). 3110–3110. 1 indexed citations
5.
Coyne, Geraldine O’Sullivan, Larry Rubinstein, Naoko Takebe, et al.. (2024). Pilot study of CBX-12 pharmacodynamics in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3187–TPS3187. 1 indexed citations
6.
Gettinger, Scott, Karen L. Reckamp, Jeffrey A. Moscow, et al.. (2024). Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A. JCO Precision Oncology. 8(8). e2300725–e2300725. 2 indexed citations
7.
Chauhan, Aman, Charles A. Kunos, Susanne M. Arnold, et al.. (2024). A phase II randomized control trial of triapine plus lutetium 177 DOTATATE versus lutetium 177 DOTATATE alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS4202–TPS4202.
8.
Shin, Sarah J., Geraldine O’Sullivan Coyne, Jennifer Zlott, et al.. (2023). Phase 2 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with granulosa cell ovarian cancer.. Journal of Clinical Oncology. 41(16_suppl). 5564–5564. 1 indexed citations
9.
Best, Ana F., Jessica Li, Andrea Denicoff, et al.. (2023). COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS). JNCI Journal of the National Cancer Institute. 115(5). 597–600. 4 indexed citations
10.
Mittra, Arjun, Geraldine O’Sullivan Coyne, Jennifer Zlott, et al.. (2023). Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors. Cancer Chemotherapy and Pharmacology. 93(3). 177–189. 2 indexed citations
11.
Johnson, Douglas B., Fengmin Zhao, Marcus Smith Noel, et al.. (2020). Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). Clinical Cancer Research. 26(8). 1812–1819. 42 indexed citations
12.
Holbeck, Susan L., Richard F. Camalier, James A. Crowell, et al.. (2017). The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity. Cancer Research. 77(13). 3564–3576. 214 indexed citations
13.
Zhao, Yingdong, Eric C. Polley, Chih-Jian Lih, et al.. (2015). GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials. Cancer Informatics. 14s2(Suppl 1). CIN.S17282–CIN.S17282. 28 indexed citations
14.
Kummar, Shivaani, Chih-Jian Lih, Eric C. Polley, et al.. (2015). Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers. JNCI Journal of the National Cancer Institute. 107(4). djv003–djv003. 41 indexed citations
15.
Kummar, Shivaani, Jiuping Ji, Robert J. Morgan, et al.. (2012). A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas. Clinical Cancer Research. 18(6). 1726–1734. 155 indexed citations
16.
Houghton, Peter J., Christopher L. Morton, Richard Görlick, et al.. (2010). Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program. Molecular Cancer Therapeutics. 9(1). 101–112. 79 indexed citations
17.
Pfister, Thomas D., Ralph E. Parchment, Shivaani Kummar, et al.. (2010). Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells. Clinical Cancer Research. 16(3). 1073–1084. 75 indexed citations
18.
Kinders, Robert J., Melinda G. Hollingshead, Scott M. Lawrence, et al.. (2010). Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity. Clinical Cancer Research. 16(22). 5447–5457. 56 indexed citations
19.
Kummar, Shivaani, Larry Rubinstein, Robert J. Kinders, et al.. (2009). Abstract #5456: Correlation between inhibition of the activity of poly(ADP-ribose) polymerase (PARP) in human peripheral blood mononuclear cells (PBMCs) and tumor biopsies following treatment with ABT-888, an inhibitor of PARP. Cancer Research. 69. 5456–5456. 6 indexed citations
20.
Thomas, Paul & Larry Rubinstein. (1993). Malignant disease appearing late after operation for T1 N0 non-small-cell lung cancer. Journal of Thoracic and Cardiovascular Surgery. 106(6). 1053–1058. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard Kaplan Breakdown of academic impact, for papers by Janet Dancey Breakdown of academic impact, for papers by Susan G. Arbuck Breakdown of academic impact, for papers by Denis Lacombe Breakdown of academic impact, for papers by Jaap Verweij Breakdown of academic impact, for papers by Elizabeth A. Eisenhauer Breakdown of academic impact, for papers by Lawrence H. Schwartz Breakdown of academic impact, for papers by Jan Bogaerts Breakdown of academic impact, for papers by Kenneth R. Hess Breakdown of academic impact, for papers by John D. Hainsworth
Rankless by CCL
2026